Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Descending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q2017 Teniposide Teniposide 50 mg Chemotherapy Plant Alkaloid Epipodophyllotoxins No 1992 July 1, 2000 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan. 1, 1984 In Use
C9289 Asparaginase Erwinaze 1,000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 April 4, 2012 Dec. 31, 2014 No Longer Used
J9019 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 2011 Jan. 1, 2013 In Use
J9266 Pegaspargase Oncaspar unspecified Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan. 1, 1996 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan. 1, 2004 In Use
J9118 Calaspargase pegol-mknl Asparlas 10 units Chemotherapy Miscellaneous Agent Enzyme No 2018 Oct. 1, 2019 In Use
J9021 Asparaginase Erwinia Chrysanthemi (recombinant)-rywn Rylaze 0.1mg Chemotherapy Miscellaneous Agent Enzyme No 2021 Jan. 26, 2022 In Use
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
C9083 Amivantamab-vmjw Rybrevant 10mg Immunotherapy Monoclonal Antibody EGFR,MET No 2021 Sept. 27, 2021 Jan. 26, 2022 No Longer Used
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan. 26, 2022 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Afatinib Gliotrif 30 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Erlotinib Tarceva 100 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
J8565 Gefitinib Iressa 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 Jan. 1, 2005 In Use
NA Osimertinib Tagrisso 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
NA Osimertinib Tagrisso 80 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb. 12, 2004 Dec. 31, 2004 No Longer Used
J9055 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Jan. 1, 2005 In Use

Found 716 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.